{"nctId":"NCT00474266","briefTitle":"Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children","startDateStruct":{"date":"2007-06-05","type":"ACTUAL"},"conditions":["Infections, Meningococcal"],"count":1000,"armGroups":[{"label":"Nimenrix + Priorix-Tetra Group","type":"EXPERIMENTAL","interventionNames":["Biological: Meningococcal vaccine GSK134612 (Nimenrix)","Biological: Priorix-Tetra"]},{"label":"Nimenrix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Meningococcal vaccine GSK134612 (Nimenrix)","Biological: Priorix-Tetra"]},{"label":"Priorix-Tetra Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Priorix-Tetra","Biological: Meningitec"]},{"label":"Meningitec Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Priorix-Tetra","Biological: Meningitec"]}],"interventions":[{"name":"Meningococcal vaccine GSK134612 (Nimenrix)","otherNames":[]},{"name":"Priorix-Tetra","otherNames":[]},{"name":"Meningitec","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.\n* A male or female between, and including, 12 and 23 months of age at the time of the vaccination.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Free of obvious health problems as established by medical history and clinical examination before entering into the study.\n* Previously completed routine childhood vaccinations to the best of parents' or legal guardians' knowledge.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.\n* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month before and 42 days after the first dose of vaccine(s).\n* Previous vaccination with meningococcal vaccine of serogroup A, C W and/or Y.\n* History of meningococcal disease.\n* Previous vaccination against measles, mumps, rubella, and/or varicella.\n* History of measles, mumps, rubella and/or varicella.\n* Known exposure to measles, mumps, rubella, varicella or zoster within 30 days prior to vaccination.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including neomycin.\n* Major congenital defects or serious chronic illness.\n* Acute disease at the time of enrolment.\n* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"23 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With rSBA-MenC, rSBA-MenA, rSBA-MenW-135, rSBA-MenY Titers Greater Than or Equal to (≥) the Cut-off Values","description":"The cut-off values for the rSBA titers were ≥ 1:8. The analysis was performed only on subjects receiving meningitis vaccination (Nimenrix) at Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"360","spread":null},{"groupId":"OG001","value":"353","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"357","spread":null},{"groupId":"OG001","value":"353","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"360","spread":null},{"groupId":"OG001","value":"354","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"359","spread":null},{"groupId":"OG001","value":"354","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-measles Antibody Concentrations ≥ the Cut-off Values","description":"The cut-off values for anti-measles antibody concentrations were ≥ 150 milli-international units per milliliter (mIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"361","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"118","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-mumps Antibody Concentrations ≥ the Cut-off Values","description":"The cut-off values for anti-mumps antibody concentrations were ≥ 231 units per milliliter (U/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"97","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-rubella Antibody Concentrations ≥ the Cut-off Values.","description":"The cut-off values for anti-rubella antibody concentrations were ≥ 4 international units per milliliter (IU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"361","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"118","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-varicella Antibody Concentrations ≥ the Cut-off Values","description":"The cut-off values for anti-varicella antibody concentrations were ≥ 1:4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"326","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"105","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off Values","description":"The cut-off values for the rSBA titers were ≥ 1:8 and ≥ 1:128 respectively. At pre-vaccination for all groups, half of the subjects were sera tested for rSBA-MenC while the other half was tested for rSBA-MenA, rSBA-MenW-135 and rSBA-MenY. At Post vaccination I (Day 42), all subjects from Nimenrix + Priorix-Tetra and Nimenrix groups were sera tested for each rSBA. For Meningitec and Priorix-Tetra groups, all subjects were tested for rSBA-MenC while half of subjects were tested for rSBA-MenA, rSBA-MenW-135 and rSBA-MenY.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"359","spread":null},{"groupId":"OG001","value":"353","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"337","spread":null},{"groupId":"OG001","value":"339","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"360","spread":null},{"groupId":"OG001","value":"352","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"112","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"358","spread":null},{"groupId":"OG001","value":"353","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers","description":"Antibody titers were expressed as geometric mean titers (GMTs). At pre-vaccination for all groups, half of the subjects were sera tested for rSBA-MenC while the other half were tested for rSBA-MenA, rSBA-MenW-135 and rSBA-MenY. At Post vaccination I (Day 42), all subjects from Nimenrix + Priorix-Tetra and Nimenrix groups were sera tested for each rSBA. For Meningitec and Priorix-Tetra groups, all subjects were tested for rSBA-MenC while half of subjects were tested for rSBA-MenA, rSBA-MenW-135 and rSBA-MenY.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"22.8","spread":null},{"groupId":"OG002","value":"24.4","spread":null},{"groupId":"OG003","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2085.9","spread":null},{"groupId":"OG001","value":"2205","spread":null},{"groupId":"OG002","value":"33.1","spread":null},{"groupId":"OG003","value":"24.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"8.5","spread":null},{"groupId":"OG003","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"519","spread":null},{"groupId":"OG001","value":"477.6","spread":null},{"groupId":"OG002","value":"11.2","spread":null},{"groupId":"OG003","value":"212.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"21.9","spread":null},{"groupId":"OG003","value":"20.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2055.8","spread":null},{"groupId":"OG001","value":"2681.7","spread":null},{"groupId":"OG002","value":"25.6","spread":null},{"groupId":"OG003","value":"25.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.4","spread":null},{"groupId":"OG001","value":"50.1","spread":null},{"groupId":"OG002","value":"71","spread":null},{"groupId":"OG003","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2282.4","spread":null},{"groupId":"OG001","value":"2729.4","spread":null},{"groupId":"OG002","value":"70","spread":null},{"groupId":"OG003","value":"31.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PSA (Anti-polysaccharide A), Anti-PSC, Anti-PSW-135 and Anti-PSY Antibodies Concentrations ≥ the Cut-off Values","description":"Anti-PS antibody concentrations were given as geometric mean concentrations (GMCs) and expressed as microgram per milliliter (μg/mL). At pre-vaccination (Day 0) and Post-vaccination I (Day 42), a quarter of the subjects were tested for anti-PSC and another quarter for anti-PSA, anti-PSW-135 and anti-PSY.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.15","spread":null},{"groupId":"OG002","value":"0.16","spread":null},{"groupId":"OG003","value":"0.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.74","spread":null},{"groupId":"OG001","value":"15.71","spread":null},{"groupId":"OG002","value":"0.16","spread":null},{"groupId":"OG003","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"0.15","spread":null},{"groupId":"OG002","value":"0.15","spread":null},{"groupId":"OG003","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.26","spread":null},{"groupId":"OG001","value":"7.44","spread":null},{"groupId":"OG002","value":"0.15","spread":null},{"groupId":"OG003","value":"4.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":null},{"groupId":"OG001","value":"0.15","spread":null},{"groupId":"OG002","value":"0.16","spread":null},{"groupId":"OG003","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"0.16","spread":null},{"groupId":"OG003","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"0.16","spread":null},{"groupId":"OG002","value":"0.15","spread":null},{"groupId":"OG003","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.56","spread":null},{"groupId":"OG001","value":"6.37","spread":null},{"groupId":"OG002","value":"0.16","spread":null},{"groupId":"OG003","value":"0.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibodies Concentrations ≥ the Cut-off Values","description":"The cut-off values for anti-PS antibody concentrations were ≥ 0.3 μg/mL and ≥ 2.0 μg/mL respectively. At pre-vaccination (Day 0) and Post-vaccination I (Day 42), a quarter of the subjects were tested for anti-PSC and another quarter for anti-PSA, anti-PSW-135 and anti-PSY.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With hSBA-MenA (Meningococcal Polysaccharide A Serum Bactericidal Antibodies Using Human Complement), hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Titers ≥ the Cut-off Values","description":"The cut-off values for hSBA antibody titers were ≥ 1:4 and ≥ 1:8 for Nimenrix + Priorix-Tetra group, Nimenrix group, Meningitec group and Pooled group (Nimenrix + Priorix-Tetra and Nimenrix groups), respectively. The analysis was performed only on subjects receiving meningitis vaccination (Nimenrix) at Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"305","spread":null},{"groupId":"OG001","value":"273","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"578","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"292","spread":null},{"groupId":"OG001","value":"261","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"553","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"339","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"677","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"336","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"675","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"280","spread":null},{"groupId":"OG001","value":"295","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"575","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"279","spread":null},{"groupId":"OG001","value":"294","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"573","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"273","spread":null},{"groupId":"OG001","value":"261","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"534","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"271","spread":null},{"groupId":"OG001","value":"261","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"532","spread":null}]}]}]},{"type":"SECONDARY","title":"hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers","description":"Anti-hSBA antibody titers were expressed as geometric mean titers (GMTs) for Nimenrix + Priorix-Tetra group, Nimenrix group, Meningitec group and Pooled group (Nimenrix + Priorix-Tetra and Nimenrix groups), respectively. The analysis was performed only on subjects receiving meningitis vaccination (Nimenrix) at Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"25.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"209.1","spread":null},{"groupId":"OG001","value":"196","spread":null},{"groupId":"OG002","value":"40.3","spread":null},{"groupId":"OG003","value":"202.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"48.9","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"52.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"2.1","spread":null},{"groupId":"OG003","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","spread":null},{"groupId":"OG001","value":"30.9","spread":null},{"groupId":"OG002","value":"2.1","spread":null},{"groupId":"OG003","value":"34.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-measles Antibody Concentrations","description":"Anti-measles antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL) in all groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4273.4","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"4457.3","spread":null},{"groupId":"OG003","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-measles Antibody Concentrations","description":"Anti-measles antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in mIU/mL in a subset (30%) of the Nimenrix + Priorix-Tetra and Priorix-Tetra groups only. The analysis was performed only on subjects receiving varicella vaccination (Priorix-Tetra) at Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7113.8","spread":null},{"groupId":"OG001","value":"8699.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-mumps Antibody Concentrations","description":"Anti-mumps antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in units per milliliter (U/mL) in all groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"662.9","spread":null},{"groupId":"OG001","value":"115.5","spread":null},{"groupId":"OG002","value":"710.1","spread":null},{"groupId":"OG003","value":"115.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-mumps Antibody Concentrations","description":"Anti-mumps antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in U/mL in a subset (30%) of the Nimenrix + Priorix-Tetra and Priorix-Tetra groups only. The analysis was performed only on subjects receiving varicella vaccination ( Priorix-Tetra) at Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3351.2","spread":null},{"groupId":"OG001","value":"3334.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-rubella Antibody Concentrations","description":"Anti-rubella antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in international units per millilier (IU/mL) in all groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"53.2","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-rubella Antibody Concentrations","description":"Anti-rubella antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in IU/mL in a subset (30%) of the Nimenrix + Priorix-Tetra and Priorix-Tetra groups only. The analysis was performed only on subjects receiving varicella vaccination (Priorix-Tetra) at Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-varicella Antibody Titers","description":"Anti-varicella antibody titers were given as geometric mean titers (GMTs) for all groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152.8","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"128.8","spread":null},{"groupId":"OG003","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-varicella Antibody Titers","description":"Anti-varicella antibody titers were given as geometric mean titers (GMTs) in a subset (30%) of the Nimenrix + Priorix-Tetra and Priorix-Tetra groups only. The analysis was performed only on subjects receiving varicella vaccination ( Priorix-Tetra) at Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4175.6","spread":null},{"groupId":"OG001","value":"3360.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local Symptoms Specific for Priorix-Tetra Vaccination","description":"Solicited local symptoms assessed were pain, redness and swelling for the Nimenrix + Priorix-Tetra Group and Priorix-Tetra Group, respectively. The analysis was performed only on subjects receiving varicella vaccination (Priorix-Tetra) at Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local Symptoms After Nimenrix or Meningitec Vaccination at Day 0","description":"Solicited local symptoms assessed were pain, redness and swelling for the Nimenrix + Priorix-Tetra Group, Nimenrix Group and Meningitec Group, respectively. The analysis was performed only on subjects receiving meningitis vaccination (Priorix-Tetra) at Day 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133","spread":null},{"groupId":"OG001","value":"136","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited General Symptoms","description":"Solicited general symptoms assessed were drowsiness, fever (measured rectally and temperature ≥ 38.0°C ), irritability and loss of appetite, Meningismus, Parotiditis and Rash.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"150","spread":null},{"groupId":"OG002","value":"48","spread":null},{"groupId":"OG003","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Priorix-Tetra - Specific Solicited General Symptoms","description":"Solicited general symptoms assessed were fever (measured rectally and temperature ≥ 38.0°C ), Meningismus, Parotiditis and Rash.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"295","spread":null},{"groupId":"OG001","value":"164","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Specific Adverse Events (AEs)","description":"Specific AEs include: rash, New Onset of Chronic Illness(es) (NOCI), and/or conditions prompting emergency room (ER) visits or non-routine physician office visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited Symptoms","description":"Unsolicited symptom covers any symptom reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null},{"groupId":"OG001","value":"225","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited Symptoms","description":"Unsolicited symptom covers any symptom reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"252","spread":null},{"groupId":"OG001","value":"233","spread":null},{"groupId":"OG002","value":"90","spread":null},{"groupId":"OG003","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization, result in disability/ incapacity or are a congenital anomaly/ birth defect in the offspring of a study subject.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":375},"commonTop":["Irritability","Erythema","Somnolence","Decrease appetite","Pain"]}}}